EA2142-Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Tumors including Poorly Differentiated Neuroendocrine Carcinomas and Well-Differentiated Neuroendocrine Neoplasms

https://clinicaltrials.gov/ct2/show/NCT02595424
Cancer - Pancreatic, Cancer - Rare
Principal Investigator: Ding Wang, MD

Gastroenteropancreatic Neuroendocrine carcinoma, pancreatic cancer, rare cancer

Accepting Participants
313-916-3731